Chronic exposure to toxaphene resulted in an increase in liver tumors in B6C3F1 mice. This study was performed to investigate the mode of action of toxaphene induced mouse liver tumors. Following an initial 14 day dietary dose range-finding study in male mice, a mechanistic study (0, 3, 32, and 320 ppm toxaphene in diet for 7, 14, and 28 days of treatment) was performed to examine the potential mechanisms of toxaphene induced mouse liver tumors. Toxaphene induced a significant increase in expression of constitutive androstane receptor (CAR) target genes (Cyp2b10, Cyp3a11) at 32 and 320 ppm toxaphene. aryl hydrocarbon receptor (AhR) target genes (Cyp1a1 and Cyp1a2) were slightly increased in expression at the highest toxaphene dose (320 ppm). No increase in peroxisome proliferator-activated receptor alpha activity or related genes was seen following toxaphene treatment. Lipid peroxidation was seen following treatment with 320 ppm toxaphene. These changes correlated with increases in hepatic DNA synthesis. To confirm the role of CAR in this mode of action, CAR knockout mice (CAR -/-) treated with toxaphene confirmed that the induction of CAR responsive genes seen in wild-type mice was abolished following treatment with toxaphene for 14 days. These findings, taken together with previously reported studies, support the mode of action of toxaphene induced mouse liver tumors is through a nongenotoxic mechanism involving primarily a CAR-mediated processes that results in an increase in cell proliferation in the liver, promotes the clonal expansion of preneoplastic lesions leading to adenoma formation.
The organochlorine pesticide toxaphene (technical toxaphene) is a mixture of multiple congeners. Although toxaphene is no longer manufactured in the United States, any residual risks may come from exposure to environmentally weathered mixtures. Technical toxaphene has been evaluated for carcinogenicity in rats and mice (NCI, 1979 ). An increased incidence of mouse liver tumors was seen in both male and female B6C3F1 mice, with male mice showing a greater incidence (NCI, 1979) . In the chronic bioassay performed by the National Cancer Institute (NCI), toxaphene was given to mice in the diet initially at concentrations of 320 ppm (high dose) and 160 ppm (low dose) as well as a control (0 ppm) group (NCI, 1979) . Due to toxicity, the doses of toxaphene were reduced during the bioassay. The final time weighted average doses of toxaphene studied resulted in concentrations of 99 ppm (for the low dose) and 198 ppm (for the high dose). At necropsy, male mice showed a dose-related increase in carcinomas and combined hyperplastic nodules (adenomas) and carcinomas. In male mice, the high dose of toxaphene resulted in a 98% incidence of liver carcinomas and the low dose produced an incidence of 69% carcinomas compared with 8% for untreated male controls. In female mice, the high dose produced an incidence of 69% carcinomas and the lower dose resulted in a 10% incidence with untreated female controls showing 0% carcinomas in the liver. By contrast, rats showed no increase in liver tumors.
Toxaphene has shown limited evidence of genotoxicity in in vitro assays that diminishes in the presence of metabolic activation and has not shown mutagenicity in in vivo assays (Lamb et al., 2008) . Mechanistic data suggest that the dose-response curve for toxaphene induced tumors in mice was nonlinear and possibly exhibits a threshold (Goodman et al., 2000) . The induction of mouse liver tumors by toxaphene appears to be through nongenotoxic mechanisms similar to that observed by other rodent liver carcinogens through receptor-mediated processes (Whysner et al., 1998) .
The mode of action by which chemicals induce liver tumors in rodents has been extensively studied. In general (Table 1) , the induction of tumors in rodents follows 1 of 2 overall courses, through either genotoxic (direct DNA reactive) or nongenotoxic mechanisms (Klaunig, 2013) . The category of nongenotoxic mechanisms can be further defined into cytotoxic, receptor mediated, oxidative stress, or infectious agents. Agents that produce tumors in the liver through cytotoxic mechanisms induce significant hepatic necrosis that results in chronic compensatory hyperplasia. This chronic hyperplasia either induces new initiated hepatocytes through misrepair of DNA and/or allows for the selective clonal expansion of preneoplastic hepatocytes already present (Klaunig, 2013) . Receptor-mediated modes of action, although involving different receptors, function though the gene expression induction of an increase in cell proliferation and increase DNA synthesis that allows for the selective clonal expansion of preneoplastic hepatocytes. Oxidative stress is seen with inflammation as well as during the metabolism of xenobiotics. Oxidative stress may also contribute to other modes of action as an associate factor or modulating factor (Corton et al., 2014) . Infectious agents similarly may induce liver cancer via consistent damage and injury, having a cytotoxic component to the mechanism of action.
Based on the previous studies, toxaphene appears to function through a nongenotoxic mode of action (Goodman et al., 2000; NCI, 1979) . In this study, an initial dose range-finding study was performed to determine the doses of toxaphene to be used for the subsequent mechanistic studies that explored multiple endpoints involved with a potential nongenotoxic mode of action of rodent liver tumor induction. The endpoints selected were based on those established previously (Elcombe et al., 2014) .
MATERIALS AND METHODS

Chemicals
The technical-grade toxaphene (CAS RN 8001-35-2) used in this study was obtained from Hercules, Inc, Wilmington, Delaware (Lot No. X-16189-49) . The chemical was stored at < 4 C and protected from light. Technical toxaphene is a mixture of up to 800 different chemicals or congeners (Simon and Manning, 2006) . The technical toxaphene used in this study was obtained from a single previously commercially manufactured batch. The chemical and physical properties of toxaphene have been previously described (ATSDR, 1996) .
Animals
Male B6C3F1 mice (5-7 weeks old) were purchased from Harlan Sprague-Dawley Co (Indianapolis, Indiana). Male constitutive androstane receptor (CAR) knockout mice (CAR -/-; C57BL/ 6-Nr1i3tm1.1Arte, 5-10 weeks old) were purchased from Taconic (Rensselaer, New York). Because CAR -/-mice were made using wild-type C57BL/6 mouse as a background strain, therefore, wild-type C57BL/6 with the same gender and similar age were also purchased from the same vender to serve as background control for this study. Mice were housed in the AAALAC certified animal facility at Indiana University, Bloomington, Indiana. All animals were maintained in accordance to the Guide for the Care and Use of Laboratory Animals from the Institute of Laboratory Animal Research (NRC, 1996) , and treatment protocols were approved by the Institutional Animal Care and Use Committee at Indiana University. Mice were housed (5 per cage) in individually ventilated cages under conditions of controlled temperature (22 C 6 1 C), humidity (40%-70%), and light cycle (12 h/12 h) and were given food and municipal water ad libitum. All animals were acclimated for 7 days prior to the initiation of the study. Individual mice were ear-tagged for identification throughout the study and randomly assigned to control or exposure groups.
Dietary Test Article Preparation and Analysis
Toxaphene was delivered in powder diet that was formulated by mixing a toxaphene stock solution with the premix AIN76a diet (Dyets Inc, Bethlehem, Pennsylvania). Diets were prepared prior to study initiation and formulated as a fixed concentration (ppm or mg/kg) of test material in the feed. Diets were placed in air tight storage containers and stored in the dark at 4 C and protected from light until use and during the treatment period. Analytical confirmation of all dose levels plus control was determined in the diets sampled prior to the initiation and upon completion of the study. Homogeneity of the test material-feed mixture was determined concurrent with dose confirmation using a hexane/acetone extraction method followed by gas chromatography/electron capture detector analysis. The results of the diet analysis (toxaphene recovery in mouse diet) are shown in supplementary Table 1 . Phenobarbital (PB), an established liver carcinogen in rodents was used as a positive control for mode of action endpoints in the mouse liver. PB diet (750 ppm) was prepared in the same way as toxaphene. No formulation analysis was conducted for the PB diet.
Study design. Three separate studies were performed to examine possible nongenotoxic mechanisms for toxaphene induced liver tumors in mice. An initial 14 day range-finding study was performed in B6C3F1 male mice (strain used in the cancer bioassay) to examine a range of toxaphene doses on liver histopathology, DNA synthesis and toxicity. Based on the results of the rangefinding study, a second, mechanism study using B6C3F1 male mice exposed to 4 toxaphene concentrations (0, 3, 32, and 320 ppm) for 7, 14, or 28 days was performed that explored possible tumorigenic modes of action. Based on the results of the mechanism study, a third study, using male Nuclear Constitutive Androstane Receptor (CAR) knockout mice and the respective wild-type mice (male C57BL/6) treated with the carcinogenic dose of toxaphene was performed.
14 day range-finding study. The range-finding study was conducted in male B6C3F1 mice to evaluate liver effects at a range of dietary doses of toxaphene. The dose range for this study was calculated from the NCI (1979) study initial maximum tolerated (40, 80, and 160 ppm) to allow evaluation of a doseresponse effect. After 1 week of acclimation period, B6C3F1 mice (n ¼ 5/dose group) were randomly assigned to 1 of 6 treatment groups. Fresh feed was provided daily and excess remaining feed was discarded. After 7 days of exposure, mice were given bromodeoxyuridine (BrdU, 0.8 mg/ml in drinking water, 1% glucose was included for palatability) for 7 days till termination for subsequent DNA synthesis measurement. BrdU containing water was changed twice weekly. All mice were sacrificed after 14 days of exposure by CO2 asphyxiation. The body weight, liver weight, and weights of other major organs of each animal were recorded. Blood was collected through cardiac puncture from each animal for hepatic enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) analyses. A necropsy was performed with particular attention to liver lesions. A portion of liver and gut (duodenum) from each animal was fixed in 10% neutral buffered formalin for histopathology by hematoxylin and eosin (H&E) staining and immunohistochemistry staining with anti-BrdU (Biogenic Laboratories, Inc, San Ramon, California). The rest of the liver was snap frozen and stored in À80 C freezer.
Mechanism study. This mechanistic study was subsequently performed in an effort to define the mode of action of toxaphene induced liver tumors in mice. Based on the results of the rangefinding study, 3 toxaphene doses (3, 32, and 320 ppm) were selected for this mechanistic study. Doses used in this study were selected based on the range-finding study along with previous exposure information reported in the chronic bioassay in the scientific literature. The high dose (320 ppm) was the highest dietary concentration tested in the NCI carcinogenicity study (NCI, 1979) . This dose did not induce toxicity (mortality, morbidity, or > 10% body weight loss) during the range-finding study. This dose did induce an increase in hepatic DNA synthesis. A mid dose (32 ppm, 1/10 of high dose) and a low dose (3 ppm, 1/100 of high dose) were chosen to further define the dose-response characteristics of the toxaphene induced mode of action related endpoints in this study. One hundred and eighty male B6C3F1 mice were assigned to this study. After acclimation (1 week), mice (36/dose group) were randomly assigned to control and treatment groups. Mice were exposed via diet to 3 concentrations of toxaphene continuously for 7, 14, or 28 days. Concurrent negative control (vehicle) and positive control (PB) groups were also tested for 7, 14, or 28 days. Twelve mice/dose group were sacrificed on each of days 7, 14, and 28 in accordance with animal care procedures. Seven days prior to each sacrifice interval, 5 mice were randomly selected per group to receive BrdU for subsequent DNA synthesis analysis. Blood and tissues were sampled in the same way as described earlier.
Constitutive androstane receptor (CAR) knockout study. Based on the results of the mechanism study, further examination of the role of CAR in the toxaphene induced carcinogenesis in the mouse was examined. A total of 30 mice (15 wild-type C57BL/6 and 15 CAR -/-mice) were treated with 320 ppm toxaphene in the diet continuously for 14 days. Concurrent negative control and positive control (phenobarbital 750 ppm) groups were also examined. After 1 week acclimation, mice were assigned to control and treatment groups (5 mice/ dose group) in a body weight stratified and random manner to minimize bias. Mice were sacrificed on day 14. Seven days prior to sacrifice, mice were given BrdU in drinking (0.8 mg/ml with 1% glucose) water for subsequent DNA synthesis measurement. Animals in all groups were placed on study the same day. Body weight of each animal was recorded weekly and at terminal sacrifice. Survival data was obtained and necropsies were performed on all animals. The liver was dissected and trimmed and removed in toto and weighed. A portion of the liver was fixed in 10% neutral buffered formalin for histopathology and immunohistochemistry analysis, and the rest were snap frozen in liquid nitrogen and stored at À80 C for enzyme activity and other analyses.
Hepatic DNA synthesis. BrdU incorporation was used to evaluate the hepatic DNA synthesis rate in the treated mice liver. BrdU incorporation rate or labeling index was detected by immunohistochemistry methods using a modified procedure previously described (Eldridge et al., 1990) . Liver samples from all lobes were used. Cells that incorporated BrdU were visualized by the accumulation of the brown pigment in the nuclei compared with the hematoxylin counterstained blue nuclei. A stretch of duodenum from each animal was included on all slides to ensure proper staining and incorporation of BrdU into the tissues. Cells in 30 random fields were counted for each animal (> 2000 cells) and labeling index (percentage of cells in S-phase) was calculated by dividing the total number of BrdU labeled nuclei by the total number of hepatocytes counted.
Hepatic enzyme activity. Liver hepatotoxicity was assessed by measuring hepatic enzyme including ALT and AST activities in serum samples. Serum samples were separated from the blood collected from each mouse. All analysis was performed by ANTECH Diagnostics (Indianapolis, Indiana).
Liver homogenate preparation. Frozen stored liver tissue (7/treatment group) from all groups was thawed on ice and homogenized using a Bullet Blender (Next Advance) in ice cold 50 mM Tris-HCl 154 mM KCl buffer (pH 7.2) at 4 C (Hoivik et al., 2004) .
The liver homogenates were centrifuged at 2500 Â g for 10 min at 4 C to remove cell debris, blood cells, and large organelles.
The resulting post nuclear supernatant were divided into several aliquots and stored at À80 C until use. Total homogenate protein for individual liver sample was determined using the Pierce BCA protein assay (Thermo Scientific, Rockford, Illinois) with bovine serum albumin as a standard (Smith et al., 1985) .
Peroxisomal acyl-CoA oxidase assay. Peroxisomal acyl-CoA oxidase (ACO) activity of homogenate was measured as the lauryl-CoA-dependent production of hydrogen peroxide. This was quantified by measuring the oxidation of 4-hydroxyphenylacetic acid to a fluorescent product with 405 nm wavelength after excitation at 320 nm wavelength in a horseradish peroxidase-coupled assay (Poosch and Yamazaki, 1986) . Measurements were performed in triplicate in a 96-well format on a fluorescence microplate reader (Tecan Infinite 200, San Jose, California).
8-isoprostane analysis. One indicator of oxidative stress is lipid peroxidation in the liver of treated mice was evaluated by measuring the isoprostane (8-iso-PGF2a), a biomarker of oxidative stress, via OxiSelect 8-iso-Prostaglandin F2a ELISA Kit obtained from Cell Biolabs (San Diego, California) according to the manufacturer's guideline. Sample protein concentration determined via BCA assay (Pierce, Rockford, Illinois) was used for normalization purposes. Results were expressed as ng/ml of 8-iso-PGF2a/mg protein.
Malondialdehyde analysis. In addition to 8-isoprostane, another lipid peroxidation marker, malondialdehyde (MDA), was assessed by assay of thiobarbituric acid-reactive substances according to the manufacture's instruction manual (Cayman). Liver tissues were homogenized in RIPA buffer supplemented with 1 mM phenylmethylsulfonyl fluoride on a Bullet Blender (Next Advance) followed by and sonication for 15 s at 40 V on ice. The optical density of the colored product was read at 532 nm. MDA standard (Cayman) was used to prepare the standard curve and the results were expressed as nmol of MDA/mg protein.
8-Hydroxydeoxyguanasine analysis. Oxidative DNA damage was evaluated by measuring 8-hydroxydeoxyguanasine (8-OHdG) in genomic DNA. Fresh snap frozen liver tissues was disrupted and homogenized in Buffer ALT (Qiagen DNeasy Blood and Tissue DNA Kit) using Bullet Blender (Next Advance). Briefly, approximately 25 mg of tissue was transferred to a microcentrifuge tube containing 200 ml of lysis buffer, and 100 mg of 0.9-2.0 mm stainless steel beads. The tissue was homogenized in the Bullet Blender at room temperature at speed 10 for 5 min.
The sample was centrifuged at full speed for 5 min. The supernatant was then transferred to a new 1.5 ml tube. Genomic DNA purification was conducted as directed by the Qiagen DNeasy Blood and Tissue Handbook. DNA was quantified by Nanodrop spectrophotometer 2000C for appropriate dilution and quality was assessed using 260/280 and 260/230 absorbance ratios. 8-OHdG levels in the isolated DNA were analyzed using commercial 8-OHdG EIA Kit (#589230, Cayman). Briefly, genomic DNA (20 mg) from above were denatured at 95 C for 5 min and then digested with nuclease P1 (2.5 units, 37 C, 120 min) and alkaline phosphatase (5 units, 37 C, 60 min), then centrifuged at 6000 Â g for 5 min. Fifty microliters of the supernatant for each sample was then used for 8-OHdG analysis following the product instructions provided in the EIA kit. Results are expressed as the ng/ml of 8-OHdG/mg protein.
Real-time PCR analysis of gene expression. The expression levels of CAR, aryl hydrocarbon receptor (AhR), peroxisome proliferatoractivated receptor alpha (PPAR-alpha) target genes, cell growth related genes, and oxidative stress related genes (Supplementary Table 2 ) were determined using real-time PCR technique. Briefly, total RNAs from frozen liver homogenate were prepared with RNeasy Plus Mini Kit (Qiagen). cDNA was synthesized with Superscript III First-Strand Synthesis System (Life Technologies) following manufacture's instruction. Quantitative real-time PCR was performed with SYBR Green detection method using the ABI PRISM 7900HT Sequence Detection System (Life Technologies). A final volume of 10 ll PCR reaction mixtures containing 5 ll Fast SYBR Green master mix (Life Technologies), each primer at 500 nM and 50 ng cDNA templates was used for each sample and in duplicate. b2 microglobulin was used as internal control. The relative expression level (fold change) of each gene was calculated using the 2(-Delta Delta C(T)) Method (Livak and Schmittgen, 2001 ).
Statistical analysis. Data are expressed as mean 6 SD (otherwise noted). Statistical difference (P < .05) from control values for all data was determined using 1-way ANOVA with Dunnett's post hoc test. If a normality test was failed, Kruskal-Wallis test (rank test) was then applied. All analyses were carried out using GraphPad Prism 5.02 (San Diego).
RESULTS
Day Range-Finding Study
Mortality and clinical observations. No mortality was observed during the 2-week study period from all dosing groups. No significant clinical manifestations were observed in any of the treated or control mice throughout the duration of the range-finding study. No noticeable gross lesions were observed in the liver or other major organs of mice in any treatment groups at necropsy.
Body and organ weights. Initial and final body weights were recorded for each mouse and after 7 days of treatment during the study. The mean body weights of the mice were not different prior to the initiation of dosing. Statistically significant body weight loss was observed in mice treated with 320 ppm toxaphene in diet upon termination (Table 2 ). Liver weight was obtained for each animal upon sacrifice, and relative liver weight (% of liver weight over body weight) was calculated. Absolute liver weights were increased in a dose-dependent manner in mice treated with 80, 160, and 320 ppm toxaphene compared with control (Table 2) . A significant dose-dependent increases in relative liver weight were also observed in mice treated with 80, 160, and 320 ppm toxaphene diet (Table 2) . No statistical differences in relative liver weight were observed following treatment with 10 and 40 ppm toxaphene diet for 14 days (Table 2) .
Liver enzyme evaluation. Hepatotoxicity following treatment with toxaphene was assessed by measuring ALT and AST activity in serum samples. As shown in Table 3 , mice exposed to toxaphene 320 ppm in diet had a statistically significant increase in serum ALT compared with control. No statistically significant change in AST activity was observed in any treatment groups after 14 days of toxaphene exposure in diet relative to control.
DNA synthesis in hepatocytes. Bromodeoxyuridine (BrdU) immunohistochemistry was performed for the assessment of hepatocytes proliferation in mouse liver. Figure 1 shows the results from the 2-week range-finding study at all dose levels studied (0, 10, 40, 80, 160 , and 320 ppm technical toxaphene in diet). Significant increases in DNA synthesis in hepatocytes were seen in mice treated with 160 and 320 ppm as compared with the control. A dose-dependent fashion was observed in the increase in BrdU labeling index, which is in agreement with that of liver weight and relative liver weight as shown in Table 2 .
Mechanistic Study
In this study, male B6C3F1 mice were treated with 0 (vehicle control), 3, 32, and 320 ppm toxaphene or phenobarbital (750 ppm) in the diet for 7, 14, and 28 days. All mice survived until planned terminal sacrifice after 7, 14, or 28 days of treatment. Observation of the mice during the whole exposure period revealed neither apparent toxicity nor behavioral changes.
Body and liver weights. The initial and terminal sacrifice body weights, absolute liver weights, and relative liver weights of mice treated with toxaphene, Phenobarbital, and the control mice in the mechanistic study are shown in Table 4 . After treatment for 7 days, there was no significant difference in final body weight of all treatment groups compared with control. After treatment with 320 ppm toxaphene in the diet for 14 and 28 days, a statistically significant decrease in terminal body weight was seen from that of the untreated control group. After 7, 14, and 28 days of treatment, both the 320 ppm toxaphene treated mice and the phenobarbital treated mice showed a significant increase in liver weight and the relative liver weight relative to the corresponding controls (Table 4) .
Hepatotoxicity evaluation. With regard to liver cytotoxicity, Table 5 shows the serum levels of liver enzymes taken from mice sampled terminally after 7, 14, and 28 days of treatment.
A statistically significant increase in serum AST levels was seen after 7 days of treatment with 32 and 320 ppm toxaphene compared with the control group. Serum levels of AST after 14 and 28 days of treatment with toxaphene or phenobarbital were not different from control. ALT serum levels were increased at all sampling times in the 320 ppm toxaphene treated mice and after 14 days of treatment in the phenobarbital treated mice when compared with value in the control group. No treatment related necrosis was evident by histopathology after exposure to any of the doses of toxaphene or phenobarbital.
Hepatic DNA synthesis. Similarly to that observed in the rangefinding study, statistically significant increases in hepatocyte DNA synthesis were seen in the mice treated with the highest toxaphene dose studied (320 ppm) compared with the untreated control mice (Fig. 2) . The DNA synthesis by BrdU labeling was predominantly confined to the centrilobular region of the hepatic lobule. Occasional mitotic figures were also observed in the 320 ppm toxaphene and phenobarbital treated mice. At 320 ppm toxaphene, a > 10-fold increase in hepatic DNA synthesis (from 0.9 % for control to 10.5 % for the 320 ppm) was seen after 7 days of treatment. This similar trend in increased DNA synthesis over control was seen at the 14 day sampling time where 12.28% labeling index was seen in the 320 ppm toxaphene compared with control liver of 1.08%. After 28 days of exposure, a slight but significant increase in DNA synthesis compared with untreated control mice was seen in the 320 ppm toxaphene treatment group although labeling index was approximately 1/3 that seen after 7 and 14 days of treatment. The positive control, phenobarbital produced an increase in DNA synthesis after 7 (approximately 10-fold) and 14 days (approximately 7-fold) of treatment over untreated control. DNA synthesis levels in phenobarbital treated mice were not significantly different than untreated control levels after 28 days of treatment (Fig. 2) .
PPAR-alpha (ACO) activity. The activation of PPAR-alpha was measured using peroxisome ACO assay. No statistically significant difference in the PPAR-alpha activity (Fig. 3) as measured by ACO activity was found following treatment with either toxaphene or phenobarbital at all sampling time points.
Oxidative stress measurement. Oxidative damage to cellular DNA and lipid were measured using 8-OHdG for oxidative DNA damage, and malondialdehyde (MDA) and 8-isoprostane for lipid peroxidation. No increase over control values was seen in 8-OHdG in the liver at any of the sampling times after toxaphene or phenobarbital treatment (Fig. 4A) . MDA showed a significant increase in mouse livers sampled after 7, 14, and 28 days with 320 ppm toxaphene over untreated control (Fig. 4B) .
Although an increase in 8-isoprostane was seen with the 2 highest toxaphene doses studied at the 28 day sampling time, these values were not statistically significant from control nor was there a significant difference in dose-response (Fig. 4C) .
Gene expression profiling. Using selected primers (Supplementary  Table 2 ), the expression levels of a panel of selected genes including CAR (Fig. 5) , AhR (Fig. 6 ), PPARa target genes (Fig. 7) , cell growth related genes (Fig. 8) , and oxidative stress genes (Fig. 9) in the liver tissues of mice treated with toxaphene 0 (control), 3, 32, and 320 ppm in diet and phenobarbital (750 ppm in diet) were determined using real-time PCR technique (Livak and Schmittgen, 2001) . Compared with control group, the expression level of CARrelated gene Cyp2b10 was increased after 7 (Fig. 5A), 14 (Fig. 5B) , and 28 (Fig. 5C ) of treatment with 32 ppm toxaphene (133-, 170-, and 1533-fold, respectively), 320 ppm toxaphene (670-, 4294-, and 6295-fold, respectively) and phenobarbital (518-, 4241-, and 8228-fold, respectively). Cyp3a11 and Cyp2b9 were also increased following treatment with 320 ppm toxaphene and phenobarbital for 7 (Fig. 5A), 14 (Fig. 5B) , and 28 days (Fig. 5C ). The increase in CAR target genes ranged from 10-to 1000-fold in comparison with the control values.
For AhR gene expression Cyp1a1, Cyp1a2, Cyp1b1, and Pon1 were selected as target genes (Fig. 6) . Cyp1a1 was increased (>2-fold) following 7 and 28 days ( Fig. 6A and 6C ) of treatment with 320 ppm toxaphene. Cyp1a2 showed over 2-to 3-fold increase after 7, 14, and 28 days ( Fig. 6B and 6C ) of exposure to 320 ppm toxaphene. A similar pattern was noticed with regards to the increase of Cyp1a1 and Cyp1a2 following treatment with phenobarbital. No significant increase in Cyp1b1 and Pon1 Five-to seven-week-old-male B6C3F1 mice were treated with technical toxaphene 0 (control), 3, 32, and 320 ppm and PB 750 ppm in diet for 7, 14, and 28
days. The activity of PPAR-alpha was measured using peroxisomal acyl-CoA oxidase (ACO) assay. No statistical difference in the ACO levels was found by 1-way ANOVA with post hoc Dunnett's test. Values represent mean 6 SD of 7 samples in each group.
expression at any sampling time was seen with phenobarbital or toxaphene exposure. Noticeably, the expression level of CAR responsive gene Cyp2b10 were 295-, 1235-and 1973-fold higher compared with that of the AhR responsive gene Cyp1a2 following exposure to toxaphene at 320 ppm for 7, 14, and 28 days, respectively (Fig. 6 ). These findings indicate that toxaphene activates primarily CAR nuclear receptors in a way similar to that of phenobarbital. None of the PPAR-alpha related gene expression (Fig. 7) including Acox1, Acot1, Cyp4a10, or Pmp70 were increased in mouse liver treated with toxaphene or phenobarbital, instead, the expression of Acot1 was decreased by 2-fold after 7 and 14 days ( Fig. 7A and 7B ) treatment with toxaphene at 32 and 320 ppm, and phenobarbital.
With regards to the expression of cell growth related genes (Fig. 8) , c-myc was elevated following treatment with high dose toxaphene and phenobarbital for 7 ( Fig. 8A ; 4-and 3-fold), 14 ( Fig. 8B ; 4-and 2-fold) and 28 days ( Fig. 8C ; 2-and 2-fold) in comparison with control. In addition, the expression of p21 gene was remarkably suppressed (> 2-fold) at all sampling points following 32 and 320 ppm toxaphene treatment. The same was observed for toxaphene 3 ppm after 14 (Fig. 8B ) and 28 days (Fig. 8C) treatment. Oxidative-stress related genes showed the highest fold increase (2-to 3-fold) over control with Aox1 in the 320 ppm toxaphene at all times examined (Fig. 9 ) and the phenobarbital at 28 day (Fig. 9C) , suggesting the involvement of 
Constitutive Androstane Receptor (CAR) Knockout Study
In this study, male wild-type C57BL/6 and CAR -/-mice were treated with toxaphene (320 ppm in diet) phenobarbital (750 ppm in diet) or nothing (vehicle control) for 14 days. No significant clinical manifestations were observed in any of the treated or control mice during the duration the study.
Effects of toxaphene on body and liver weights OF wild-type C57BL/6 and CAR -/-mice. The body weight and body weight gain of CAR -/-mice were not significantly different between toxaphene or phenobarbital and untreated control following 14 days of treatment. After 14 days, both toxaphene and phenobarbital exposed C57BL/6 mice showed a significant increase in absolute liver weight and relative liver weight (P < .05; Table 6 ). No statistical difference were observed in both the absolute and relative liver weight in CAR -/-mice treated with toxaphene or phenobarbital for 14 days compared with untreated controls (Table 6 ).
Effects of toxaphene and PB on hepatocyte DNA synthesis in wild type C57BL/6 and CAR -/-mice. DNA synthesis was evaluated using BrdU labeling in treated wild type and CAR -/-mice following exposure. Wild type C57BL/6 mice treated with toxaphene (at 320 ppm) showed a significant increase in hepatic DNA days. The expression levels of a AhR target genes including Cyp1a1, Cyp1a2, Cyp1b1, and Pon1 in the livers of mice treated with toxaphene 3, 32, and 320 ppm in diet and phenobarbital 750 ppm and a vehicle control in diet for 7 (A), 14 (B), and 28 days (C) were determined using real-time PCR technique. B2M was used as internal control for normalization. The relative expression level (fold change) of each gene was calculated using the 2(-Delta Delta C(T)) Method. Four samples in each group were randomly selected for analysis. *P < .05 by 1-way ANOVA followed by Dunnett's test. Values represent mean 6 SE.
FIG. 7.
Mechanistic study: PPAR-alpha target gene expression in the livers of B6C3F1 mice treated with toxaphene or PB for 7, 14, and 28 days. The expression levels of a PPAR-alpha target genes including Acox1, Acot1, Cyp4a10, and Pmp-70 in the livers of mice treated with toxaphene 3, 32, and 320 ppm in diet and phenobarbital 750 ppm and a control diet for 7 (A), 14 (B), and 28 days (C) were determined using real-time PCR technique. B2M was used as internal control for normalization. The relative expression level (fold change) of each gene was calculated using the 2(-Delta Delta C(T)) Method. Four samples in each group were randomly selected for analysis. *P < .05 by 1-way ANOVA followed by Dunnett's test. Values represent mean 6 SE.
synthesis as evidenced by BrdU labeling index compared with the untreated control after 14 days of treatment (over 10-fold increase over control). PB also produced a significant increase in hepatic DNA synthesis after 14 days of treatment (over a 5-fold increase over control) ( Table 7) . In CAR -/-mice, the hepatic DNA synthesis in both toxaphene and phenobarbital treated mice did not differ from that seen in untreated CAR -/-mice ( Table 7) .
Effects of toxaphene on oxidative stress in wild-type C57BL/6 and CAR -/-mice. Treatment of wild-type C57BL/6 mice for 14 days with Toxaphene produced a slight but statistically significant increase in liver lipid peroxidation (MDA) over untreated control mice (Table 8) . PB treatment did not increase lipid peroxidation after 14 days of treatment. In toxaphene or phenobarbital treated CAR -/-mice no increase in liver MDA was seen after 14 days of treatment (Table 8) .
Effects of toxaphene on transcriptional expression of nuclear receptor related genes in wild-type C57BL/6 and CAR -/-mice. Transcriptional expression levels of nuclear receptor CAR, AhR responsive genes, as well as cell growth and oxidative stress related genes were measured as noted earlier. Given the demonstration of the lack of support for a role of PPAR-alpha in toxaphene induced liver changes from the mechanism study earlier, PPAR-alpha was not studied further. The expression level of CAR-regulated genes Cyp3a11, Cyp2b9, and Cyp2b10 was increased in wild-type C57BL/6 mice following 14 days of treatment with toxaphene 320 ppm and phenobarbital 750 ppm in diet (Fig. 10A) . The increase of CAR target genes range from 30-to 590-fold in toxaphene treated mice and 14-400 in phenobarbital treated mice over control. In   FIG. 8 . Mechanistic study: growth-related gene expression in the livers of B6C3F1 mice treated with toxaphene or PB for 7, 14, and 28 days. The expression levels of cell growth related genes including Ccnd1, Cdc25a, C-myc, and P21 in the livers of mice treated with toxaphene 3, 32, and 320 ppm in diet and phenobarbital 750 ppm and a control diet for 7 (A), 14 (B), and 28 days (C) were determined using real-time PCR technique. B2M) was used as internal control for normalization. The relative expression level (fold change) of each gene was calculated using the 2(-Delta Delta C(T)) Method. Four samples in each group were randomly selected for analysis. *P < .05 by 1-way ANOVA followed by Dunnett's test. Values represent mean 6 SE.
FIG. 9.
Mechanistic study: oxidative stress-related gene expression in the livers of B6C3F1 Mice treated with toxaphene or PB for 7, 14, and 28 days. The expression levels of oxidative stress related genes including Nrf2, Gpx1, Cat, Sod1, Sod2, and Aox1 in the livers of mice treated with toxaphene 3, 32, and 320 ppm in diet and phenobarbital 750 ppm and a control diet for 7 (A), 14 (B), and 28 days (C) were determined using real-time PCR technique. B2M was used as internal control for normalization. The relative expression level (fold change) of each gene was calculated using the 2(-Delta Delta C(T)) Method. Four samples in each group were randomly selected for analysis. *P < .05 by 1-way ANOVA followed by Dunnett's test. Values represent mean 6 SE.
contrast, in CAR -/-mice Cyp3a11, Cyp2b9, and Cyp2b10 were not significantly modified from that of control after treatment with toxaphene or phenobarbital for 14 days (Fig. 10B ). Among the AhR target genes examined (Fig. 11) , Cyp1a2 was induced in wild-type C57BL/6 after treatment with toxaphene and phenobarbital at both sampling times. Though not statistically significant, the expression level of Cyp1a1 gene was also higher (3-to 5-fold) in the treated wild-type C57BL/6 mice compared with control ( Fig. 11A ) However, transcription levels of all the AhR target genes were not increased in the CAR deficient mice following treatment with toxaphene or phenobarbital for 14 days (Fig. 11B) .
The results of cell growth related genes was also examined in wild-type C57BL/6 mice and CAR -/-mice. C-myc was upregulated (up to 2-fold) without statistical significance in the C57BL/ 6 mice treated with toxaphene for 14 days (data not shown). In addition, oxidative stress related genes were examined. Aox1, which encodes aldehyde oxidase 1, was the only gene that was induced (approximately 2-fold) in the C57BL/6 mice following treatment with both toxaphene and phenobarbital. This observation was similar to that seen in the B6C3F1 mice (above). In contrast, the expression level of both the C-myc and the Aox1 genes was not significantly increased in CAR -/-mice exposed to toxaphene or phenobarbital (data not known).
DISCUSSION
Toxaphene has been shown to induce liver tumors in at least 2 mouse carcinogenicity studies (Litton-Bionetics, 1978; NCI, 1979) . Although the mechanism for the induction of mouse liver tumors had not been completely resolved, a previous report by Goodman et al. (2000) examined all of the available scientific evidence at the time and concluded that the toxaphene induced tumors in mice was nonlinear and exhibited a threshold. It has been concluded that toxaphene functions through non DNA days. The expression of CAR target genes including Cyp3a11, Cyp2b9, and Cyp2b10 in the livers of C57BL/6 and CAR -/-mice treated with toxaphene at 320 ppm or phenobarbital at 750 ppm in diet for 14 days were determined using real-time PCR technique as described in the Material and Methods section. B2M
was used as internal control for normalization. The relative expression level (fold change) of each gene was calculated using the 2(-Delta Delta C(T)) Method (Livak and Schmittgen, 2001 ). *P < .05 by 1-way ANOVA followed by Dunnett's test. Values represent mean 6 SE of 5 samples in each group. reactive /nongenotoxic mechanisms in producing liver tumors in mice, in a manner similar to that of phenobarbital, an accepted nongenotoxic rodent liver tumor promoter (Goodman et al., 2000; Whysner et al., 1998) . The mode of action by which chemicals induce liver tumors in rodents has been extensively studied. In general (Table 1) , the induction of tumors in rodents follows 1 of 2 overall courses, through genotoxic (direct DNA reactive) or nongenotoxic mechanisms (Klaunig, 2013) . Nongenotoxic mechanisms can be furthered characterized as to cytotoxic, receptor mediated, oxidative stress, or infectious agents. Agents that produce tumors in the liver through cytotoxic means induce significant necrosis to hepatocytes resulting in consistent compensatory hyperplasia. This chronic hyperplasia either induces new initiated hepatocytes through misrepair of DNA and/or allows for the selective clonal expansion of preneoplastic hepatocytes already present. Receptor-mediated modes of action, although involving different receptors, function though similar processes, ie, they result in an increase in cell proliferation and increase DNA synthesis that again allows for the selective clonal expansion of initiated preneoplastic hepatocytes. Oxidative stress is seen with inflammation as well as during the metabolism of xenobiotics by futile cycling of P450 and therefore may contribute to other modes of action as an associate or modulating factor. However, divalent metals such as copper and iron can produce reactive oxygen species through Fenton and Haber Weiss reactions resulting in indirect DNA damage as well as modulation cell growth gene expression. Infectious agents similarly may induce liver cancer via consistent damage and injury, having a cytotoxic component to the mechanism of action.
The purpose of the current investigation was to further examine mechanisms of action by which toxaphene modulates the key events involved in liver tumorigenesis as a means of helping to define the mouse liver tumor mode of action for toxaphene. The studies performed examined those endpoints (key events linked to various modes of action) ( Table 1) . It is important to note that in defining the mode of action negative findings are as important as positive results because the negative findings help eliminate alternate modes of action. The results obtained in this study utilized a short term in vivo model to examine those important endpoints that included key events in nongenotoxic liver mode of action.
The results confirmed the previous suggestion by Goodman et al. (2000) that the induction of liver tumors in the mouse by toxaphene is through threshold dependent, dose responsive mechanisms. Increases in absolute liver weight and relative liver weight (Tables 2) were seen at 80, 160, and 320 ppm of toxaphene with a dose-response pattern. Correspondingly, the BrdU labeling was also increased in a dose-dependent manner in the dose ranges tested with statistical significance seen in the 160 and 320 ppm toxaphene group (Fig. 1) . PB, which was used as a positive control for the nongenotoxic mode of action, also produced an increase in absolute liver weight, relative liver weight and DNA synthesis (Table 4 and Fig. 2) . The increase in cell proliferation was further substantiated by an increase in C-myc gene and decrease in P21 gene expression (Fig. 9) at the same dose of toxaphene (320 ppm) and phenobarbital that induced an increase in labeling index. The proto-oncogene C-myc plays an important role in driving cell proliferation as well as cancer development. It has been reported that the decrease in P21 expression is a result of C-myc upregulation (Jung and Hermeking, 2009) , which has been shown to be a consequence of CAR activation (Blanco-Bose et al., 2008) . These observations clearly point to dose response for these surrogate markers of nongenotoxic activity in the liver of the mouse.
Based on the results obtained, it is apparent that toxaphene is not functioning through a cytotoxic mode of action. Although a slight increase in liver serum enzymes were observed at the highest dose examined, histopathology confirmed that toxaphene does not produce extensive necrosis and resulting compensatory hyperplasia.
With regard to oxidative stress, no increase in liver oxidative DNA damage was seen. However an increase in lipid peroxidation (MDA) was seen with the highest dose of toxaphene studied (320 ppm). In addition, in the gene expression array for oxidative stress, Aox1 which codes aldehyde oxidase 1 was increased at the 320 ppm dose. Aldehyde oxidase produces hydrogen peroxide and, under certain conditions, can catalyze the formation of superoxide. Technical toxaphene has been shown to activate human neutrophils in vitro to produce reactive oxygen species which led to chemotaxis and accelerated apoptosis (Gauthier et al., 2001; Lavastre et al., 2002 ). An increase in aldehyde oxidase was seen in fatty liver and other liver lipid peroxidation settings (Neumeier et al., 2006; Shaw and Jayatilleke, 1990) . Thus, there appears some support for involvement of oxidative stress (specifically lipid peroxidation) at the highest dose of toxaphene examined (320 ppm), it may be more of a reflection of minor cytotoxicity at this dose as demonstrated by an increase in serum liver enzymes. It is important to note that the highest dose studied (320 ppm) is above the eventual MTD used in the chronic 2 year NCI bioassay (NCI, 1979) . Although the 320 ppm dose was initially used as the highest dose in mice in the NTP bioassay, it was lowered to 160 ppm due to toxicity and poor health of the mice after the start of the study. Nuclear receptor activation is a common mode of action for nongenotoxic chemicals that induced liver toxicity/carcinogenicity in rodents. Therefore, a receptor-mediated mode of action was examined by looking at 3 prominent receptors: AhR, CAR, and PPAR-alpha, which have been shown previously to be implicated in mouse liver carcinogenesis (Budinsky et al., 2014; Corton et al., 2014; Elcombe et al., 2014) . Our results clearly show that PPAR-alpha is not involved in the induction of the liver changes associated with toxaphene exposure (Figs. 3 and 7) . The negative response produced by phenobarbital for the PPARalpha endpoint is further confirmation as one would not expect to see an increase in PPAR-alpha activity or gene expression with phenobarbital. The results with CAR-responsive genes are very convincing. Both toxaphene and phenobarbital induced significant increase in CAR related genes especially for Cyp2b10 at all times sampled for phenobarbital (ranging from 518-to 8228-fold over control), and for both of the highest doses of toxaphene studied (with 133-to 1533-fold and 671-to 6295-fold for 32 and 320 ppm, respectively) (Fig. 5) . The expression of AhR target gene Cyp1a1 and Cyp1a2 was also induced by toxaphene and phenobarbital, however at a remarkably lower scale (2-to 3-fold over control) compared with that of CAR target gene (up to 6000-fold over control) (Fig. 6) .
There have been previous reports of a similar difference in the CAR and AhR responsive gene expression results for phenobarbital (Dehn et al., 2005) , and that phenobarbital also induced Cyp1a2 which is primarily a AhR related gene (Corcos et al., 1998; Geter et al., 2014; Sakuma et al., 1999) . This findings have been attributed to cross talk between the CAR and AhR receptors such that activation of 1 receptor can lead to the upregulation of the other receptor related gene expression and activity (Fraser et al., 2012; Patel et al., 2007) . PB induced upregulation of Cyp1a2 has been shown to be independent of AhR (Corcos et al., 1998; Sakuma et al., 1999) . Therefore, the induction of AhR target genes in this study is most likely attributable to CAR activation instead of an AhR-dependent activation.
Following the mechanism study employing B6C3F1 male mice, further examination of the role of CAR in mediating the toxaphene effects was performed using wild-type C57BL/6 mice and CAR -/-mice. This third study using CAR -/-mice further confirmed that a functional CAR is necessary for the observed effects of toxaphene (as well as phenobarbital) on increases in liver and relative liver weight, hepatic DNA synthesis, and activation of CAR. In CAR -/-mice DNA synthesis was not induced by either toxaphene or phenobarbital. Similarly, the induction of CAR target genes Cyp3a11 and Cyp2b10 by toxaphene and phenobarbital in CAR -/-mice was abolished. These observations in the CAR -/-mice clearly demonstrate that, similar to phenobarbital, toxaphene induction of Cyp3a11 and Cyp2b10 is essentially CAR-dependent and the induction of AhR target genes Cyp1a1 and Cyp1a2 is secondary to CAR activation. With regard to oxidative stress, aldehyde oxidase 1 gene (Aox1) and lipid peroxidation MDA were elevated in toxaphene treated wild-type C57BL/6 mouse similar to that seen in wildtype B6C3F1. In the CAR -/-mice, the increase in both MDA and
Aox1 seen in the wild-type mice after toxaphene treatment was prevented. Although oxidative stress is concluded not a key or associative event or a modulating factor in the mode of action of phenobarbital liver tumor promotion (Elcombe et al., 2014) , the role of oxidative stress in toxaphene induced liver effects requires further study though the data suggest that induction of Aox1 may be secondary of CAR activation. Evidence from this study clearly define CAR activation as the primary pathway in toxaphene induced mouse liver tumors. We conclude that the mode of action of toxaphene induced mouse liver tumors is through nongenotoxic mechanisms involving CAR-mediated processes that result in an increase in DNA synthesis in the liver which results in the promotion and clonal expansion of preneoplastic lesions leading to neoplastic lesion formation in the mouse liver following chronic exposure.
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